Successful €7.8m capital increase with preferential subscription rights for THX Pharma
Portzamparc Groupe BNP Paribas advised THX Pharma (www.theranexus.com), a pharmaceutical company specialized in rare neurological diseases, on its €7.8 million capital increase with preferential subscription rights (DPS).
Portzamparc Groupe BNP Paribas acted as Sole Global Coordinator of the transaction.
👉 Details of the transaction:
Capital increase of €7.8m through the issuance of 4,356,804 new shares at a price of €1.80 per share.
Strong participation from existing shareholders, with 1,742,660 shares subscribed on an irreducible and reducible basis.
Overall demand (irreducible, reducible and free) represented 1,931,202 shares, a 44.3% subscription rate.
The remaining shares were subscribed by financial investors and certain shareholders under guarantee commitments, for a total of 2,645,874 shares.
The funds raised will accelerate the development of THX Pharma’s key programs Batten-1 and TX01 and support its antisense oligonucleotide platform.
Lock-up commitments of 180 days were undertaken by founders and by the Company.
